47 results about "Brain trauma" patented technology

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The present invention belongs to the technical field of medicine. Disclosed are a class of magnolol / honokiol derivatives, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are magnolol / honokiol nitrone derivatives as represented by general formulas (I) and (II). Such derivatives are prepared by means of artificial synthesis. Further provided are a pharmaceutical composition containing same, and the use thereof against inflammation, against cerebral infarction, in the treatment of amyotrophic lateral sclerosis, and against cerebral trauma.

The invention is applicable to the field of brain-computer interfaces and rehabilitation medicine, and provides a brain injury function training device based on a brain-computer interface, which comprises a support frame, an electroencephalogram acquisition module, a signal processing module, a training control module, a feedback module, an evaluation module and a user interaction module, in the first stage, accurate collection and preprocessing of electroencephalogram signals are achieved through a flexible electrode array and a low-noise amplification and self-adaptive noise reduction technology; secondly, through linkage of an evaluation module and a training control module, dynamic optimization of a personalized training scheme is achieved; thirdly, constructing a visual, auditory and tactile multi-mode feedback and quantitative evaluation closed loop; according to the brain injury function training device, the problems that an existing device is low in electroencephalogram signal collection precision, fixed in training scheme and lack of a training-evaluation-adjustment closed loop are solved, the accuracy, adaptability and user participation degree of brain injury function training are improved, and the brain injury function training device is suitable for function recovery training of movement, cognition, language and the like of brain injury patients with cerebral apoplexy, cerebral trauma and the like.

The invention discloses a 2-(piperidinyl) pyridazinone compound (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-(piperidinyl) pyridazinone compound, a pharmaceutical composition of the 2-(piperidinyl) pyridazinone compound and application of the 2-(piperidinyl) pyridazinone compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The present invention relates to the field of medicine, and specifically to the use of taraxasterol or its salts in the preparation of drugs for preventing or treating traumatic brain injury. Animal experiments have confirmed that the taraxasterol of the present invention can improve the motor ability of the balance beam experiment in the neurological function score of mice with brain trauma, improve the neurological function scores including motor tests and sensory tests; reduce the permeability of the blood-brain barrier, reduce brain edema, improve the short-term lesion volume after traumatic brain injury, and inhibit microglial activation and immune cell infiltration. Cytological experiments have confirmed that taraxasterol can reduce microglia-mediated neuroinflammation, reduce the expression of inflammatory factors such as TNF-α, IL-6, and IL-1β, and reduce neuronal damage.

The invention discloses ursodesoxycholic acid and amino acid conjugates (I), pharmaceutically acceptable salts thereof, a preparation method of the ursodesoxycholic acid and amino acid conjugates, a pharmaceutical composition of the ursodesoxycholic acid and amino acid conjugates and application of the ursodesoxycholic acid and amino acid conjugates in preparation of drugs for treating and / or preventing comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses application of a gene editing virus interfering expression and secretion of enzyme prototype cathepsin D in brain trauma, belongs to the field of gene functions and application, and finds that brain injury is aggravated and nerve dysfunction is aggravated due to the fact that the level of the enzyme prototype cathepsin D in plasma is increased due to the brain trauma through detection. The mechanism is as follows: the enzyme prototype cathepsin D enhances the transendocytosis effect of cerebral vascular endothelial cells after brain trauma, so that plasma inflammatory factors are gathered in damaged brain tissues; meanwhile, the expression of cerebrovascular endothelial cells VCAM-1 is also up-regulated, and neutrophil infiltration in an injured brain region after brain trauma is intensified. Research finds that down-regulation of plasma enzyme prototype cathepsin D can alleviate inflammatory factor concentration and neutrophil density in a brain injury area after trauma, and alleviate neurological function impairment of mice. Aiming at the functions of the plasma prototype cathepsin D, a strategy for reducing the plasma level of the plasma prototype cathepsin D by a gene editing technology for interfering the prototype cathepsin D is provided for treating the cerebral trauma.

The invention discloses an aminoamide alkyl thioester compound (I), pharmaceutically acceptable salts thereof, a preparation method of the aminoamide alkyl thioester compound, a pharmaceutical composition of the aminoamide alkyl thioester compound and application of the aminoamide alkyl thioester compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The invention discloses an amide alkyl thiol ester compound (I) as well as a preparation method and a pharmaceutical composition thereof, and application of the amide alkyl thiol ester compound in preparation of drugs for treating and / or preventing diseases by resisting oxidative stress, inhibiting amyloid protein aggregation and resisting neuroinflammation. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases; # imgabs0 #

The present invention relates to the use of 3,4-dihydro-2H-benzo-[1,4]oxazine drugs or salts thereof in the preparation of drugs for inhibiting ferroptosis, in particular to the use of 3,4-dihydro-2H-benzo-[1,4]oxazine compounds or salts thereof in the preparation of drugs for treating ferroptosis-related diseases, wherein the ferroptosis-related diseases include brain trauma, stroke, cardiovascular disease, liver and kidney failure, inflammation and neurodegenerative diseases, such as Parkinson's disease and schizophrenia.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

This invention belongs to the field of pharmaceutical application technology, specifically relating to a folic acid derivative, its preparation method, and its application in preventing and treating ferroptosis. The folic acid derivative of this invention comprises compounds represented by general formula (I) and their pharmaceutically acceptable salts. The folic acid compounds provided by this invention, by introducing a lipophilic group or a specific group at the R position, yield compounds with good ferroptosis inhibitory activity, which can be used to treat non-alcoholic steatohepatitis, acute liver injury, cardiomyopathy, drug-induced cardiotoxicity, atherosclerosis, acute kidney injury, renal fibrosis, pneumonia, preeclampsia, osteoporosis, osteoarthritis, traumatic brain injury, and neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and epilepsy.

A method for treating low-level blast traumatic brain injury includes administering a phosphodiesterase-5 (PDE5) inhibitor, such as sildenafil, to a subject following exposure of the subject to one or more low-level blasts. Administration of the PDE5 inhibitor may prove useful with respect to improving the vascular integrity of a subject by increasing brain capillary respiration, mitochondrial respiration, mitochondrial density, mitochondrial biogenesis, astrocyte level or homeostasis, and / or tight junction protein expression in the brain of the subject and / or inducing positive metabolic change in the subject by increasing NAD+ / NADH metabolism. Methods for mitigating the effects of blast injury on the vascular integrity of a subject and inducing metabolic change are also provided.

The invention provides a cerebral trauma semi-dark band image segmentation method and device, equipment, a medium and a product, and the method comprises the steps: obtaining at least two modal magnetic resonance images, inputting the at least two modal magnetic resonance images into a trained feature fusion module for fusion, and obtaining a fusion image; and inputting the fused image into a trained segmentation module for image segmentation to obtain a cerebral trauma semi-dark band region. According to the invention, the automatic identification of the cerebral trauma penumbra region is realized, and the identification efficiency of the cerebral trauma penumbra region is improved.

The invention belongs to the technical field of medical treatment, and relates to a method for constructing an animal traumatic brain injury model based on low-intensity pulsed ultrasound regulation and application thereof. The method comprises the following steps: (1) establishing a TBI mouse by adopting controlled cortical injury so as to simulate neurological impairment caused by open brain trauma; (2) setting low-intensity pulse ultrasonic conditions, and performing low-intensity pulse ultrasonic treatment on the TBI mouse; and (3) comparing the influence of the space learning and long-term memory ability of the TBI mouse before and after the low-intensity pulsed ultrasound treatment and the change of the intracerebral clearance ability, and detecting the level of phosphorylated tau protein in the damaged cerebral hemisphere, if the influence on the TBI mouse has statistical significance, judging that the TBI mouse is damaged by the phosphorylated tau protein. And if not, constructing a low-intensity pulsed ultrasound regulation animal traumatic brain injury model by using the low-intensity pulsed ultrasound condition. By regulating and controlling the key parameters of the low-intensity pulsed ultrasound, the brain lymphatic drainage and nerve repair of traumatic brain injury of animals can be regulated and controlled.

The invention discloses 2-sulfur-3-(piperidinedithio) phthalide (I), pharmaceutically acceptable salts thereof, a preparation method of the 2-sulfur-3-(piperidinedithio) phthalide (I), a pharmaceutical composition of the 2-sulfur-3-(piperidinedithio) phthalide (I) and application of the 2-sulfur-3-(piperidinedithio) phthalide (I) in preparation of drugs for treating and comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

This invention provides an artificial dura mater material, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the shortcomings of traditional synthetic dura mater, this invention utilizes poly(L-lactide-caprolactone) (PLCL) with a specific concentration of RAPA, processed using electrospinning. It exhibits low porosity and a dense texture, inducing rapid endothelialization of the dura mater in the early stages of traumatic brain injury. Subsequently, with the release of RAPA, the material's porosity increases, facilitating the proliferation and growth of newly formed dura mater cells. Simultaneously, RAPA can prevent excessive proliferation of new endothelial cells and scar hyperplasia. It can selectively inhibit pathological proliferation without impairing necessary lymphatic drainage; while maintaining the physical structural integrity of the dura mater, it can promote neurological function repair.

This utility model relates to the field of rehabilitation training devices, and particularly to a rehabilitation training device for promoting awakening in patients with severe traumatic brain injury and persistent coma. It includes a bed frame, with a pillow fixedly connected to the upper rear part of the bed frame. A first arm movement device is movably connected to the left rear part of the bed frame, and a second arm movement device is movably connected to the right rear part of the bed frame. This rehabilitation training device for patients with severe traumatic brain injury and persistent coma utilizes the first arm movement device. The patient's arm is placed within a first and second support plate, and the arm is restrained by straps. When a motor is activated, it drives a transmission rod to rotate, which in turn rotates a connecting block and the first support plate on its right side. This allows the first and second support plates to reciprocate at different angles, thereby enabling the patient's arm to move and facilitating awakening and rehabilitation.

The invention discloses a multi-modal fusion portable cerebral trauma first-aid navigation system and method, and relates to the technical field of cerebral trauma first-aid navigation. The system comprises a handheld navigation device, a data acquisition module, a pose resolving module, a feature extraction module and a boundary recognition module. The handheld navigation equipment integrates a miniature ultrasonic probe and a 9-axis inertial measurement unit, a data acquisition module synchronously acquires intracranial ultrasonic echo sequence data and spatial motion parameters, and a pose resolving module resolves the spatial motion parameters in real time to determine real-time spatial pose data of the equipment in a head coordinate system. The feature extraction module inputs the ultrasonic echo sequence data into a pre-trained convolutional neural network model to output a multi-scale ultrasonic feature vector, and the boundary recognition module generates hematoma boundary dynamic labeling information in combination with the multi-scale ultrasonic feature vector and the real-time spatial pose data. The system is suitable for scenes of on-site first aid, patient transfer and the like, and assists medical staff in mastering the intracranial hematoma condition.

The present invention discloses a class of 3-benzyloxy-6-pyridylpyridazine compounds (I) and pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof, and use thereof in preparing a drug for treating and / or preventing diseases by inhibiting monoamine oxidase B, metal ion complexation, or anti-neuroinflammation, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, prion disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and nerve damage caused by brain trauma; #imgabs0#

The invention discloses amine alkoxy cotinine compounds (I), pharmaceutically acceptable salts thereof, a preparation method of the amine alkoxy cotinine compounds, a pharmaceutical composition of the amine alkoxy cotinine compounds and application of the amine alkoxy cotinine compounds in preparation of drugs for treating and / or preventing nervous system diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The invention discloses a 3-(piperidine alkyl dithioalkyl) phthalide compound (I), pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof and application of the 3-(piperidine alkyl dithioalkyl) phthalide compound in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The invention discloses an amide alkyl thiol ketal compound (I), pharmaceutically acceptable salts thereof, a preparation method of the amide alkyl thiol ketal compound, a pharmaceutical composition of the amide alkyl thiol ketal compound, and application of the amide alkyl thiol ketal compound in preparation of drugs for treating and / or preventing nervous system related diseases and myocardial ischemia related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic cerebral thrombosis, nerve injury caused by cerebral trauma, myocardial ischemic injury and other diseases;

A method for constructing a predictive model for the 28-day mortality risk of patients with severe traumatic brain injury (sTBI) includes: collecting clinical data of patients undergoing sTBI surgery; screening samples that meet the inclusion and exclusion criteria and grouping them according to 28-day survival; collecting clinical indicators of the samples and calculating serum sodium variability on the 8th postoperative day; screening candidate variables using LASSO regression and simplifying variables through correlation analysis and multicollinearity diagnosis; dividing the dataset into training and test sets, and determining independent predictors through univariate and multivariate logistic regression analysis; constructing a nomogram prediction model based on the independent predictors, and validating the model performance through ROC curve, calibration curve, and decision curve analysis. The predictive model of this invention uses GCS score, oxygenation index, and 8-day serum sodium variability as core indicators, exhibiting high predictive accuracy and strong clinical operability, providing a quantitative basis for prognostic assessment and clinical intervention for sTBI patients.

The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, the pharmaceutical composition having improved stability by reducing the content of a crisdesalazine-related substance and having an improved dissolution rate by improving its inherent solubility. The present invention also relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, the pharmaceutical composition comprising crisdesalazine or a salt thereof, the pharmaceutical composition comprising crisdesalazine or a salt thereof, the pharmaceutical composition comprising crisdesalazine or a salt thereof. According to the composition disclosed by the invention, the stability and the bioavailability are ensured; and therefore, in the treatment of neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy associated with free radical neurotoxicity, cerebral trauma, spinal cord injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerotic inflammation, and the like), stress disorders (anxiety disorder, dyspepsia, etc. ), and the like.

This invention discloses a class of 3-substituted phthalide compounds (I) and their pharmaceutically acceptable salts, their preparation methods, pharmaceutical compositions, and their use in the preparation of drugs for the treatment and / or prevention of neurological diseases, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion's disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and neurological damage caused by traumatic brain injury;

The invention discloses a 3-(piperidine alkyl sulfide or seleno) phthalide compound (I), pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition and application thereof in preparation of drugs for treating and / or preventing nervous system related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic stroke, nerve injury caused by cerebral trauma and other diseases;

The present invention belongs to the technical field of medicine. Disclosed are a pyranocarbazole derivative and a preparation method therefor, and a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are pyranocarbazole derivatives as represented by general formulas I and II. The derivative is prepared by means of artificial synthesis. Further disclosed are a pharmaceutical composition containing the derivative, and the use thereof in resisting inflammation, resisting ischemic cerebral injury, relieving pain, resisting brain trauma, treating post-stroke depression, treating vascular dementia and cerebral small vessel disease, resisting Alzheimer's disease, and treating amyotrophic lateral sclerosis.

The invention relates to the technical field of biomedical experiment equipment, and discloses an animal experiment device for simulating decelerated brain trauma, the animal experiment device comprises a base, the side wall of the base is slidably connected with a fixing frame, the upper side of the base is provided with an impact assembly, the exterior of the fixing frame is fixedly connected with a fixing block, and the fixing block is fixedly connected with the impact assembly. And a limiting assembly is arranged outside the fixing block, a second clamping groove is formed in the fixing frame, a threaded rod is in threaded connection with the interior of the fixing frame, a rotating disc is fixedly connected to one end of the threaded rod, and an adjusting block is arranged at the other end of the threaded rod. The head of an experimental mouse is placed in the fixing block, and the rotating disc is rotated to drive the threaded rod to move back and forth in the fixing frame, so that the posture of the experimental mouse can be ensured to be unchanged in the impact process, and meanwhile, the angle of the head of the experimental mouse is adjusted and kept until the experimental mouse is impacted, namely, the impact angle is controlled; and the accuracy of experimental data is improved.